Yuan-Yeh Kuo

TL;DR: TET2 mutation is associated with poor prognosis in AML patients with intermediate-risk cytogenetics, especially when it is combined with other adverse molecular markers.

TL;DR: The DNMT3A mutation may be a potential biomarker for monitoring of minimal residual disease and an independent poor prognostic factor for overall survival and relapse-free survival in total patients and also in normokaryotype group.

TL;DR: Recurrent somatic mutation of SRSF2, one of the RNA splicing machinery genes, has been identified in a substantial proportion of patients with myelodysplastic syndrome and is associated with distinct clinical and biologic features in patients.

TL;DR: TP53 mutations are associated with distinct clinic-biological features and poor prognosis in de novo AML patients and are rather stable during disease progression, whereas the mutation was acquired only in 1 of the 126 TP53 wild-type patients when therapy-related AML originated from different clone emerged.

TL;DR: Partial tandem duplication of the MLL gene is associated with increased expression of CD11b on leukemic blasts and implicates poor prognosis in adult AML patients and the higher frequency of MLL duplication in children older than 1 year, than in other age groups, needs to be confirmed by further studies.